Expert panelists review current and emerging treatment approaches in myeloproliferative neoplasms, with focused discussion on monitoring, sequencing, and combination therapy strategies using JAK inhibitors in myelofibrosis.
April 26th 2023
A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.
Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.